Characteristics of patients with CLL for which plasma was analyzed before initiation of therapy (n = 228)
| Characteristic . | No. (%) . | P† . | ||
|---|---|---|---|---|
| Group C* . | Group D* . | Group E* . | ||
| No. of patients | 143 | 31 | 54 | |
| Median age (range), y | 57 (27-77) | 58 (40-77.5) | 68 (33-85) | <.0001 |
| Sex | ||||
| Female | 36 (25) | 11 (35) | 18 (33) | .33 |
| Male | 107 (75) | 20 (65) | 36 (67) | |
| Rai stage | ||||
| 0-II | 106 (74) | 17 (55) | 36 (67) | .1 |
| III-IV | 37 (26) | 14 (45) | 18 (33) | |
| Median β-2-microglobulin levels (range), mg/L‡ | 3.3 (1.3-10.3) | 2.3 (1.3-4.3) | 4.3 (1.6-10.2) | <.0001 |
| No data | 0 | 10 (32.26) | 0 | |
| ZAP70 expression | ||||
| Positive | 74 (52) | 13 (42) | 26 (48) | .32 |
| Negative | 64 (45) | 16 (52) | 15 (28) | |
| No data | 5 (3) | 2 (6) | 13 (24) | |
| IgHV mutation status | ||||
| Mutated | 36 (25) | 12 (39) | 10 (19) | .1 |
| Unmutated | 99 (69) | 16 (52) | 40 (74) | |
| No data | 8 (5) | 3 (9) | 4 (7) | |
| FISH results¶ | ||||
| 13q deletion | 14 (10) | 8 (26) | 10 (19) | .08 |
| Negative | 19 (13) | 8 (26) | 7 (13) | |
| Trisomy 12 | 9 (6) | 6 (19) | 12 (22) | |
| 11q deletion | 24 (17) | 2 (7) | 18 (33) | |
| 17p deletion | 7 (5) | 1 (3) | 4 (7) | |
| No data | 70 (49) | 6 (19) | 3 (6) | |
| Median time to treatment (range), months | 19 (0.07-190.49) | 24 (0-252.48) | 77 (4.53-215.79) | <.0001 |
| Response to treatment | ||||
| Complete response | 112 (78) | 12 (39) | 7 (13) | .0005 |
| Nodular partial response | 12 (8) | 0 (0) | 6 (11) | |
| Partial response | 14 (10) | 14 (45) | 17 (31) | |
| No response | 5 (4) | 5 (16) | 24 (45) | |
| Characteristic . | No. (%) . | P† . | ||
|---|---|---|---|---|
| Group C* . | Group D* . | Group E* . | ||
| No. of patients | 143 | 31 | 54 | |
| Median age (range), y | 57 (27-77) | 58 (40-77.5) | 68 (33-85) | <.0001 |
| Sex | ||||
| Female | 36 (25) | 11 (35) | 18 (33) | .33 |
| Male | 107 (75) | 20 (65) | 36 (67) | |
| Rai stage | ||||
| 0-II | 106 (74) | 17 (55) | 36 (67) | .1 |
| III-IV | 37 (26) | 14 (45) | 18 (33) | |
| Median β-2-microglobulin levels (range), mg/L‡ | 3.3 (1.3-10.3) | 2.3 (1.3-4.3) | 4.3 (1.6-10.2) | <.0001 |
| No data | 0 | 10 (32.26) | 0 | |
| ZAP70 expression | ||||
| Positive | 74 (52) | 13 (42) | 26 (48) | .32 |
| Negative | 64 (45) | 16 (52) | 15 (28) | |
| No data | 5 (3) | 2 (6) | 13 (24) | |
| IgHV mutation status | ||||
| Mutated | 36 (25) | 12 (39) | 10 (19) | .1 |
| Unmutated | 99 (69) | 16 (52) | 40 (74) | |
| No data | 8 (5) | 3 (9) | 4 (7) | |
| FISH results¶ | ||||
| 13q deletion | 14 (10) | 8 (26) | 10 (19) | .08 |
| Negative | 19 (13) | 8 (26) | 7 (13) | |
| Trisomy 12 | 9 (6) | 6 (19) | 12 (22) | |
| 11q deletion | 24 (17) | 2 (7) | 18 (33) | |
| 17p deletion | 7 (5) | 1 (3) | 4 (7) | |
| No data | 70 (49) | 6 (19) | 3 (6) | |
| Median time to treatment (range), months | 19 (0.07-190.49) | 24 (0-252.48) | 77 (4.53-215.79) | <.0001 |
| Response to treatment | ||||
| Complete response | 112 (78) | 12 (39) | 7 (13) | .0005 |
| Nodular partial response | 12 (8) | 0 (0) | 6 (11) | |
| Partial response | 14 (10) | 14 (45) | 17 (31) | |
| No response | 5 (4) | 5 (16) | 24 (45) | |
Group C: patients treated at The University of Texas MD Anderson Cancer Center with FCR as frontline therapy; group D: patients treated at the University of Southern California, San Diego, with FCR as salvage treatment; group E: patients treated at The University of Texas MD Anderson Cancer Center with lenalidomide.
For categorical data (sex/Rai stage/ZAP70 expression/IgHV mutation status/FISH results/response to treatment), the Fisher exact test was used to calculate P values; for continuous variables (age/median B2M levels/time to treatment), the Kruskal-Wallis test was used.
No data were available for 10 patients.
FISH assay performed using bone marrow samples.